Neuraminidase inhibitors for treatment of influenza A and B infections.
Identifieur interne : 000369 ( PubMed/Corpus ); précédent : 000368; suivant : 000370Neuraminidase inhibitors for treatment of influenza A and B infections.
Auteurs :Source :
- MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports [ 1057-5987 ] ; 1999.
English descriptors
- KwdEn :
- Acetamides (administration & dosage), Acetamides (adverse effects), Acetamides (pharmacokinetics), Acetamides (therapeutic use), Adolescent, Adult, Antiviral Agents (administration & dosage), Antiviral Agents (adverse effects), Antiviral Agents (pharmacokinetics), Antiviral Agents (therapeutic use), Drug Interactions, Drug Resistance, Microbial, Enzyme Inhibitors (administration & dosage), Enzyme Inhibitors (adverse effects), Enzyme Inhibitors (pharmacokinetics), Enzyme Inhibitors (therapeutic use), Guanidines, Humans, Influenza A virus, Influenza B virus, Influenza, Human (drug therapy), Neuraminidase (antagonists & inhibitors), Oseltamivir, Pyrans, Sialic Acids (administration & dosage), Sialic Acids (adverse effects), Sialic Acids (pharmacokinetics), Sialic Acids (therapeutic use), Zanamivir.
- MESH :
- chemical , administration & dosage : Acetamides, Antiviral Agents, Enzyme Inhibitors, Sialic Acids.
- chemical , adverse effects : Acetamides, Antiviral Agents, Enzyme Inhibitors, Sialic Acids.
- chemical , antagonists & inhibitors : Neuraminidase.
- chemical , pharmacokinetics : Acetamides, Antiviral Agents, Enzyme Inhibitors, Sialic Acids.
- chemical , therapeutic use : Acetamides, Antiviral Agents, Enzyme Inhibitors, Sialic Acids.
- drug therapy : Influenza, Human.
- Adolescent, Adult, Drug Interactions, Drug Resistance, Microbial, Guanidines, Humans, Influenza A virus, Influenza B virus, Oseltamivir, Pyrans, Zanamivir.
Abstract
Influenza epidemics are responsible for an average of approximately 20,000 deaths per year in the United States. The main method for preventing influenza and its severe complications is influenza vaccination. Influenza-specific antiviral drugs are an important adjunct to vaccine but are not a substitute for vaccine. In the United States, four antiviral agents are approved for preventing or treating influenza: amantadine, rimantadine, zanamivir, and oseltamivir. Amantadine was approved for prophylaxis of influenza A(H2N2) infection in the United States in 1966 and was approved for prophylaxis and treatment of influenza A infection in 1976; rimantadine was approved for treatment and prophylaxis of influenza A infection in 1993 [corrected]. This report provides information on two neuraminidase inhibitors, zanamivir and oseltamivir, which were approved in 1999. Neuraminidase inhibitors are a new class of antiviral drugs that inhibit influenza A and B viruses. Zanamivir is approved for treatment of uncomplicated acute illness caused by influenza virus in persons aged > or =12 years who have been symptomatic for no more than 2 days. Oseltamivir is approved for treatment of uncomplicated illness caused by influenza infection in adults aged > or =18 years who have been symptomatic for no more than 2 days. Neither zanamivir nor oseltamivir is approved for influenza prophylaxis. This report and the Advisory Committee on Immunization Practices (ACIP) 1999 recommendations on influenza prevention and control (MMWR 1999;48[No.RR-4]:1-28) can be accessed at the website for the Influenza Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, CDC, at or at the MMWR website at .
PubMed: 10632443
Links to Exploration step
pubmed:10632443Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neuraminidase inhibitors for treatment of influenza A and B infections.</title>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1999">1999</date>
<idno type="RBID">pubmed:10632443</idno>
<idno type="pmid">10632443</idno>
<idno type="wicri:Area/PubMed/Corpus">000369</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000369</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Neuraminidase inhibitors for treatment of influenza A and B infections.</title>
</analytic>
<series><title level="j">MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports</title>
<idno type="ISSN">1057-5987</idno>
<imprint><date when="1999" type="published">1999</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acetamides (administration & dosage)</term>
<term>Acetamides (adverse effects)</term>
<term>Acetamides (pharmacokinetics)</term>
<term>Acetamides (therapeutic use)</term>
<term>Adolescent</term>
<term>Adult</term>
<term>Antiviral Agents (administration & dosage)</term>
<term>Antiviral Agents (adverse effects)</term>
<term>Antiviral Agents (pharmacokinetics)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Drug Interactions</term>
<term>Drug Resistance, Microbial</term>
<term>Enzyme Inhibitors (administration & dosage)</term>
<term>Enzyme Inhibitors (adverse effects)</term>
<term>Enzyme Inhibitors (pharmacokinetics)</term>
<term>Enzyme Inhibitors (therapeutic use)</term>
<term>Guanidines</term>
<term>Humans</term>
<term>Influenza A virus</term>
<term>Influenza B virus</term>
<term>Influenza, Human (drug therapy)</term>
<term>Neuraminidase (antagonists & inhibitors)</term>
<term>Oseltamivir</term>
<term>Pyrans</term>
<term>Sialic Acids (administration & dosage)</term>
<term>Sialic Acids (adverse effects)</term>
<term>Sialic Acids (pharmacokinetics)</term>
<term>Sialic Acids (therapeutic use)</term>
<term>Zanamivir</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Acetamides</term>
<term>Antiviral Agents</term>
<term>Enzyme Inhibitors</term>
<term>Sialic Acids</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Acetamides</term>
<term>Antiviral Agents</term>
<term>Enzyme Inhibitors</term>
<term>Sialic Acids</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Neuraminidase</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Acetamides</term>
<term>Antiviral Agents</term>
<term>Enzyme Inhibitors</term>
<term>Sialic Acids</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Acetamides</term>
<term>Antiviral Agents</term>
<term>Enzyme Inhibitors</term>
<term>Sialic Acids</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Drug Interactions</term>
<term>Drug Resistance, Microbial</term>
<term>Guanidines</term>
<term>Humans</term>
<term>Influenza A virus</term>
<term>Influenza B virus</term>
<term>Oseltamivir</term>
<term>Pyrans</term>
<term>Zanamivir</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Influenza epidemics are responsible for an average of approximately 20,000 deaths per year in the United States. The main method for preventing influenza and its severe complications is influenza vaccination. Influenza-specific antiviral drugs are an important adjunct to vaccine but are not a substitute for vaccine. In the United States, four antiviral agents are approved for preventing or treating influenza: amantadine, rimantadine, zanamivir, and oseltamivir. Amantadine was approved for prophylaxis of influenza A(H2N2) infection in the United States in 1966 and was approved for prophylaxis and treatment of influenza A infection in 1976; rimantadine was approved for treatment and prophylaxis of influenza A infection in 1993 [corrected]. This report provides information on two neuraminidase inhibitors, zanamivir and oseltamivir, which were approved in 1999. Neuraminidase inhibitors are a new class of antiviral drugs that inhibit influenza A and B viruses. Zanamivir is approved for treatment of uncomplicated acute illness caused by influenza virus in persons aged > or =12 years who have been symptomatic for no more than 2 days. Oseltamivir is approved for treatment of uncomplicated illness caused by influenza infection in adults aged > or =18 years who have been symptomatic for no more than 2 days. Neither zanamivir nor oseltamivir is approved for influenza prophylaxis. This report and the Advisory Committee on Immunization Practices (ACIP) 1999 recommendations on influenza prevention and control (MMWR 1999;48[No.RR-4]:1-28) can be accessed at the website for the Influenza Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, CDC, at or at the MMWR website at .</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10632443</PMID>
<DateCompleted><Year>2000</Year>
<Month>01</Month>
<Day>12</Day>
</DateCompleted>
<DateRevised><Year>2016</Year>
<Month>10</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">1057-5987</ISSN>
<JournalIssue CitedMedium="Print"><Volume>48</Volume>
<Issue>RR-14</Issue>
<PubDate><Year>1999</Year>
<Month>Dec</Month>
<Day>17</Day>
</PubDate>
</JournalIssue>
<Title>MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports</Title>
<ISOAbbreviation>MMWR Recomm Rep</ISOAbbreviation>
</Journal>
<ArticleTitle>Neuraminidase inhibitors for treatment of influenza A and B infections.</ArticleTitle>
<Pagination><MedlinePgn>1-9</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Influenza epidemics are responsible for an average of approximately 20,000 deaths per year in the United States. The main method for preventing influenza and its severe complications is influenza vaccination. Influenza-specific antiviral drugs are an important adjunct to vaccine but are not a substitute for vaccine. In the United States, four antiviral agents are approved for preventing or treating influenza: amantadine, rimantadine, zanamivir, and oseltamivir. Amantadine was approved for prophylaxis of influenza A(H2N2) infection in the United States in 1966 and was approved for prophylaxis and treatment of influenza A infection in 1976; rimantadine was approved for treatment and prophylaxis of influenza A infection in 1993 [corrected]. This report provides information on two neuraminidase inhibitors, zanamivir and oseltamivir, which were approved in 1999. Neuraminidase inhibitors are a new class of antiviral drugs that inhibit influenza A and B viruses. Zanamivir is approved for treatment of uncomplicated acute illness caused by influenza virus in persons aged > or =12 years who have been symptomatic for no more than 2 days. Oseltamivir is approved for treatment of uncomplicated illness caused by influenza infection in adults aged > or =18 years who have been symptomatic for no more than 2 days. Neither zanamivir nor oseltamivir is approved for influenza prophylaxis. This report and the Advisory Committee on Immunization Practices (ACIP) 1999 recommendations on influenza prevention and control (MMWR 1999;48[No.RR-4]:1-28) can be accessed at the website for the Influenza Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, CDC, at or at the MMWR website at .</AbstractText>
</Abstract>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>MMWR Recomm Rep</MedlineTA>
<NlmUniqueID>101124922</NlmUniqueID>
<ISSNLinking>1057-5987</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000081">Acetamides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006146">Guanidines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011714">Pyrans</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012794">Sialic Acids</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>20O93L6F9H</RegistryNumber>
<NameOfSubstance UI="D053139">Oseltamivir</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber>
<NameOfSubstance UI="D009439">Neuraminidase</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>L6O3XI777I</RegistryNumber>
<NameOfSubstance UI="D053243">Zanamivir</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>MMWR Morb Mortal Wkly Rep 1999 Dec 17;48(49):1139</RefSource>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000081" MajorTopicYN="N">Acetamides</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004352" MajorTopicYN="N">Drug Resistance, Microbial</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006146" MajorTopicYN="N">Guanidines</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009981" MajorTopicYN="N">Influenza B virus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009439" MajorTopicYN="N">Neuraminidase</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053139" MajorTopicYN="N">Oseltamivir</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011714" MajorTopicYN="N">Pyrans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012794" MajorTopicYN="N">Sialic Acids</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053243" MajorTopicYN="N">Zanamivir</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year>
<Month>1</Month>
<Day>13</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2000</Year>
<Month>2</Month>
<Day>19</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2000</Year>
<Month>1</Month>
<Day>13</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">10632443</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000369 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000369 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= H2N2V1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:10632443 |texte= Neuraminidase inhibitors for treatment of influenza A and B infections. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:10632443" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a H2N2V1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |